دورية أكاديمية
Real-world impact of infliximab precision-guided dosing on management of patients with IBD.
| العنوان: | Real-world impact of infliximab precision-guided dosing on management of patients with IBD. |
|---|---|
| المؤلفون: | Abraham BP, Ziring DA, Dervieux T, Han PA, Shim A; Prometheus Laboratories Inc, 9410 Carroll Park Dr, San Diego, CA 92121. Email: ashim@prometheuslabs.com., Battat R |
| المصدر: | The American journal of managed care [Am J Manag Care] 2023 Oct; Vol. 29 (12 Suppl), pp. S227-S235. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Clinical Care Targeted Communications Group, LLC Country of Publication: United States NLM ID: 9613960 Publication Model: Print Cited Medium: Internet ISSN: 1936-2692 (Electronic) Linking ISSN: 10880224 NLM ISO Abbreviation: Am J Manag Care |
| أسماء مطبوعة: | Publication: Cranbury, NJ : Clinical Care Targeted Communications Group, LLC Original Publication: Old Bridge, NJ : American Medical Pub., c1995- |
| مواضيع طبية MeSH: | Gastrointestinal Agents*/therapeutic use , Inflammatory Bowel Diseases*/drug therapy, Humans ; Infliximab/therapeutic use ; Prospective Studies ; Bayes Theorem ; Drug Monitoring/methods |
| مستخلص: | Objectives: Evaluate the clinical utility of a precision-guided dosing test for infliximab (IFX) and its impact on treatment decision-making for inflammatory bowel disease (IBD). Study Design: Prospective, multisite, clinical experience program. Methods: Health care providers were given access to PredictrPK IFX, a precision-guided dosing test, for their patients with IBD on maintenance IFX therapy. Blood samples were drawn 20 to 56 days post infusion. A Bayesian data assimilation tool used clinical and serologic data to generate individual pharmacokinetic profiles and forecast trough IFX. Results were reported to providers to aid in-therapy management decisions and the decision-making process was assessed through questionnaires. Relationships between forecasted IFX concentration, disease activity, and therapy management decisions were analyzed by logistic regression. Results: PredictrPK IFX was used for 275 patients with IBD by 37 providers. In 58% of cases, providers modified treatment plans based on the results, including dose modifications (41%; of these, one-third decreased dose) and discontinuation (8%) of IFX. Of the 42% where treatment was not modified, 97.5% had IFX levels of 5 µg/mL or greater. Patients with IFX concentrations less than 5 µg/mL were 3 and 7.3 times more likely to have active disease or discontinue IFX, respectively. There was unanimous agreement among providers who completed a postprogram survey that PredictrPK IFX was beneficial in guiding treatment decisions and added more value to their practice than routine therapeutic drug monitoring. Conclusions: PredictrPK IFX enables earlier and more precise dose optimization of IFX in patients with IBD, exerting a substantial impact on treatment decisions that may result in improved health outcomes and overall cost savings. |
| المشرفين على المادة: | B72HH48FLU (Infliximab) 0 (Gastrointestinal Agents) |
| تواريخ الأحداث: | Date Created: 20231016 Date Completed: 20231023 Latest Revision: 20231111 |
| رمز التحديث: | 20240628 |
| DOI: | 10.37765/ajmc.2023.89447 |
| PMID: | 37844322 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1936-2692 |
|---|---|
| DOI: | 10.37765/ajmc.2023.89447 |